Grifols (Grifols) Net Change in Cash

: $0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Grifols's Net Change in Cash for the three months ended in Dec. 2023 was $0 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 was $0 Mil.

Grifols Net Change in Cash Historical Data

The historical data trend for Grifols's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Change in Cash

Get a 7-Day Free Trial

-324.23

-197.49

2,368.32

-2,253.85

-20.07

Grifols Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Net Change in Cash	Get a 7-Day Free Trial															-	-	-	-	-

Grifols Net Change in Cash Calculation

Grifols's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	227.135	+	-433.627	+	202.884	+	-16.46
	=	-20

Grifols's Net Change in Cash for the quarter that ended in Dec. 2023

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= 0 + 0 + 0 + 0

= 0

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grifols Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Grifols's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Grifols (Grifols) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (NAS:GRFS) » Definitions » Net Change in Cash

Comparable Companies

XMAD:AEDAS XMAD:NEA XMAD:BKT XMAD:ALB XMAD:NTH XMAD:AZK XMAD:BST XMAD:TRE XMAD:ACX XMAD:ELE LLY JNJ MRK ABBV LSE:AZN XSWX:ROG XSWX:NOVN PFE AMGN XPAR:SAN

Traded in Other Exchanges

GIKLY:USA GIFOF:USA GIFLF:USA GRFP:Mexico GRFe:UK GRFPe:UK 0RDV:UK 0RDU:UK GRF.P:Spain GRF:Spain G0F0:Germany G0F:Germany G0FB:Germany OZTA:Germany OZTA:Germany G0FB:Germany

Address

Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174

Website

https://www.grifols.com

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's biopharma business contributed 83% of sales in 2022. Grifols also has smaller segments including diagnostics and biosupplies. Diagnostics is roughly 10% of revenue following the Biotest acquisition.

Grifols (Grifols) Headlines

From GuruFocus

Grifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin�-C in Patients with Emphysema Due to Alpha-1-Antitrypsin Deficiency
By Marketwired • 07-13-2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Grifols S.A. - GRFS
By PRNewswire • 01-14-2024

GigaGen Granted Expansion of Contract with US Department of Defense to Develop Synthetic Human Antibody Treatments for Botulinum Neurotoxins
By Marketwired • 10-19-2023

Grifols partners with Feeding America� to help address hunger in the U.S.
By PRNewswire PRNewswire • 03-02-2022

GigaGen Publishes Research Demonstrating the Potential of its Machine Learning Platform to Improve Antibody Drug Discovery and Development
By GuruFocusNews GuruFocusNews • 05-29-2022

Grifols Launches AlphaID� At Home, Enabling U.S. Consumers to Self-Screen for Genetic COPD
By sperokesalga sperokesalga • 05-11-2023

GRFS SHAREHOLDER ALERT: Johnson Fistel Investigates Grifols, S.A. Following Short Seller Report
By Business Wire • 01-09-2024

GigaGen Publishes Research Demonstrating the Potential of its Machine Learning Platform to Improve Antibody Drug Discovery and Development
By GuruFocusNews GuruFocusNews • 07-08-2022

GigaGen Partners with the National Cancer Institute to Advance Oncology Drug Candidate GIGA-564
By Marketwired • 09-28-2023

Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein� (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis
By Marketwired • 07-18-2023